Needham & Company LLC Reaffirms Hold Rating for TransMedics Group (NASDAQ:TMDX)

Needham & Company LLC restated their hold rating on shares of TransMedics Group (NASDAQ:TMDX) in a research note released on Friday, Marketbeat reports. They currently have a $109.00 price target on the stock.

TMDX has been the subject of several other research reports. Piper Sandler decreased their price objective on TransMedics Group from $180.00 to $110.00 and set an “overweight” rating for the company in a report on Wednesday, November 20th. Stephens lifted their target price on shares of TransMedics Group from $151.00 to $178.00 and gave the stock an “overweight” rating in a research note on Friday, August 2nd. Baird R W upgraded shares of TransMedics Group to a “strong-buy” rating in a research note on Tuesday, September 24th. TD Cowen reduced their price objective on shares of TransMedics Group from $175.00 to $120.00 and set a “buy” rating for the company in a research note on Monday, November 18th. Finally, Robert W. Baird dropped their target price on TransMedics Group from $200.00 to $150.00 and set an “outperform” rating on the stock in a research report on Tuesday, October 29th. Two investment analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $131.80.

TransMedics Group Stock Performance

NASDAQ TMDX opened at $78.58 on Friday. The company has a debt-to-equity ratio of 2.42, a quick ratio of 7.33 and a current ratio of 8.20. The company has a market capitalization of $2.64 billion, a PE ratio of 83.60 and a beta of 2.08. TransMedics Group has a 52-week low of $67.77 and a 52-week high of $177.37. The company has a 50-day simple moving average of $117.72 and a 200 day simple moving average of $137.49.

TransMedics Group (NASDAQ:TMDX) last posted its quarterly earnings results on Monday, October 28th. The company reported $0.12 EPS for the quarter, missing analysts’ consensus estimates of $0.29 by ($0.17). TransMedics Group had a return on equity of 18.74% and a net margin of 8.14%. The company had revenue of $108.76 million during the quarter, compared to the consensus estimate of $115.00 million. During the same period last year, the firm posted ($0.12) EPS. The company’s revenue for the quarter was up 63.7% compared to the same quarter last year. On average, research analysts predict that TransMedics Group will post 1 EPS for the current year.

Insider Buying and Selling

In related news, insider Tamer I. Khayal sold 2,958 shares of the firm’s stock in a transaction that occurred on Tuesday, October 1st. The shares were sold at an average price of $148.24, for a total value of $438,493.92. Following the sale, the insider now directly owns 20,843 shares of the company’s stock, valued at $3,089,766.32. This trade represents a 12.43 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Waleed H. Hassanein sold 8,625 shares of TransMedics Group stock in a transaction that occurred on Tuesday, October 15th. The shares were sold at an average price of $132.71, for a total transaction of $1,144,623.75. Following the sale, the chief executive officer now owns 61,643 shares of the company’s stock, valued at approximately $8,180,642.53. The trade was a 12.27 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 26,958 shares of company stock worth $3,470,328. Corporate insiders own 7.00% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the company. Russell Investments Group Ltd. boosted its stake in TransMedics Group by 337,462.5% in the first quarter. Russell Investments Group Ltd. now owns 27,005 shares of the company’s stock worth $1,997,000 after buying an additional 26,997 shares in the last quarter. State Board of Administration of Florida Retirement System grew its holdings in shares of TransMedics Group by 8.6% during the 1st quarter. State Board of Administration of Florida Retirement System now owns 9,843 shares of the company’s stock valued at $745,000 after purchasing an additional 780 shares during the last quarter. Vanguard Group Inc. grew its holdings in shares of TransMedics Group by 1.3% during the 1st quarter. Vanguard Group Inc. now owns 1,889,094 shares of the company’s stock valued at $139,680,000 after purchasing an additional 23,979 shares during the last quarter. Price T Rowe Associates Inc. MD raised its position in TransMedics Group by 8.1% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 297,324 shares of the company’s stock worth $21,985,000 after purchasing an additional 22,223 shares during the period. Finally, Public Employees Retirement System of Ohio bought a new stake in TransMedics Group in the first quarter worth $1,588,000. Institutional investors own 99.67% of the company’s stock.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.